Fresenius SE & Co. KGaA

2026 (May–Aug)

Strong operational momentum and upgraded guidance following Q1 and Q2 results. S&P revised its outlook to positive, and the company issued bonds. Market perception shifted toward "Rejuvenate" execution — investors saw Fresenius converting restructuring gains into sustainable earnings growth and balance-sheet repair. Upgraded guidance and improved credit outlook reinforced a narrative of transition from turnaround to growth with financial stability.

Q1/2026 performance showed group revenue of €5,744m with organic growth of 5%. Core EPS grew 13% in constant currency.

Q2/2026 delivered group revenue of €5,864m with organic growth of 6%. Group EBIT reached €719m with a margin of 12.3%. Core EPS grew 14% in constant currency to €0.83 for the half-year.

S&P affirmed the BBB rating and revised its outlook from Stable to Positive during February–May 2026, announced alongside 2026 results.

On July 8, 2026, Fresenius issued €1,000m in bonds [10].

2025 (full year; results announced Feb 25, 2026)

FY/2025 results launched the "Rejuvenate" phase of #FutureFresenius. Management upgraded guidance during the year and continued portfolio simplification, including a decision to reduce its stake in Fresenius Medical Care. Investors interpreted 2025 as the pivot from restructuring to growth: after RESET and Revitalize phases, management presented Rejuvenate as the value-creation phase. Consistent organic growth, margin improvement, and deleveraging shifted sentiment from cyclical recovery toward sustainable operational improvement.

Group revenue for FY/2025 reached €22,554m with organic growth of 7%. EBIT grew 13% in constant currency and Core EPS grew 12% in constant currency (excluding Fresenius Medical Care). Management stated net debt had been reduced by approximately €3bn over the prior two years through end-2025. The company announced a proposal to increase the dividend at the 2026 AGM [9][16][18][22].

2024 (calendar year and FY/2024 disclosures)

Continued execution of the #FutureFresenius strategy (Reset → Revitalize) with portfolio moves and improving profitability across core businesses, preparing for Rejuvenate in 2025. Markets increasingly viewed Fresenius as de-risked — operational focus on higher-return growth vectors (Fresenius Kabi growth initiatives, Helios hospital performance) and disciplined portfolio management improved investor confidence, though legacy exposure to Fresenius Medical Care and leverage remained watchpoints.

FY/2024 reported revenue of approximately €21.8bn with headline EPS improvements versus 2023. The RESET phase initiated in 2022 was followed by Revitalize actions through 2023–2024 [11][19].

2023 (operational focus, portfolio optimization)

Ongoing Revitalize actions focused on building "growth vectors" (notably in Fresenius Kabi) and continued portfolio optimization; operational improvement at Fresenius Helios hospital network. Investors began to reward clearer strategy and early signs of margin recovery. Sentiment moved from caution about execution risk toward guarded optimism as core businesses delivered steady results and management emphasized returns and cash-generation priorities.

Public disclosures and investor communications repeatedly cited progressing Growth Vectors and margin improvement in core divisions across Fresenius Kabi and Helios [3][19].

2022 (Oct 1, 2022 — Management change and Reset strategy launch)

Michael Sen was appointed CEO effective October 1, 2022; the company announced and began implementing "RESET" — focus on returns, productivity, and balance-sheet repair. The management change signaled a strategic reset; markets saw the move as a decisive management-level step to fix structural issues (leverage, margins). Initial investor perception was that of a high-risk / high-reward turnaround: success would mean restored profitability and de-risking, failure would leave legacy problems unresolved.

The RESET phase was documented in subsequent Annual Reports and investor materials as commencing in 2022, focusing on return metrics and productivity improvements [11][19].

2021 (context: pandemic aftermath and business pressures)

Post-COVID normalization in healthcare demand and continued pressure on some business lines (costs, supply-chain, and outpatient services) set the stage for the 2022–2025 strategic program. Investors treated Fresenius as still recovering from pandemic-related revenue shifts and structural challenges; the company's multi-year strategy to rebuild margins and reduce leverage was not yet evidence-backed, so sentiment was cautious and valuation reflected execution risk [19].